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Abstract
Neisseria meningitidis recruits host human complement inhibitors to its surface to down-reg-
ulate complement activation and enhance survival in blood. We have investigated whether
such complement inhibitor binding occurs after vaccination with native outer membrane vesi-
cles (nOMVs), and limits immunogenicity of such vaccines. To this end, nOMVs reactogenic
lipopolysaccharide was detoxified by deletion of the lpxl1 gene (nOMVlpxl1). nOMVs unable to
bind human complement factor H (hfH) were generated by additional deletions of the genes
encoding factor H binding protein (fHbp) and neisserial surface protein A (NspA) (nOMVdis).
Antibody responses elicited in mice with nOMVdis were compared to those elicited with
nOMVlpxl1 in the presence of hfH. Results demonstrate that the administration of human fH to
mice immunized with fHbp containing OMVlpxl1 decreased immunogenicity against fHbp (but
not against the OMV as a whole). The majority of the OMV-induced bactericidal immune
response (OMVlpxl1 or OMVdis) was versus PorA. Despite a considerable reduction of hfH
binding to nOMVdis, and the absence of the vaccine antigen fHbp, immunogenicity in mice
was not different from nOMVlpxl1, in the absence or presence of hfH (serum bactericidal titers
of 1:64 vs 1:128 after one dose in the nOMVdis and nOMVlpxl1–immunized groups respec-
tively). Therefore, partial inhibition of fH binding did not enhance immunity in this model.
Introduction
Neisseria meningitidis is a human-restricted pathogen, which causes meningitis and sepsis,
which may result in death or long-term disabilities. The attack rate is highest in young children
and adolescents [1]. Based on the carbohydrate composition, thirteen capsular groups of N.
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meningitidis have been described. Groups A, B, C,W and Y are the most prevalent worldwide [2]
with efficacious protein-polysaccharide conjugate vaccines being available for groups A, C,W and
Y. Since polysaccharide-based vaccines against MenB are not efficacious [3], research has focused
on sub-capsular antigens for MenB vaccines [4]. Vaccines containing recombinant proteins (used
in the two licensed vaccines currently available) and outer membrane vesicles (OMVs) have been
used. OMV vaccines have proved especially useful during clonal MenB outbreaks [5, 6].
Native OMVs have potentially higher adjuvant capacity as compared to chemically detoxi-
fied OMVs due to the retention of lipopolysaccharide (LPS) [7], but also contain several pro-
teins that bind complement inhibitors including factor H (fH), C4bp and activated vitronectin
[8–11]. Binding of such complement inhibitors could potentially reduce the immunogenicity
of nOMVs through decreased activation of innate immunity, as alerting and priming the
immune system is now a well-recognized function of the complement [12]. A reduction of this
signal could result in reduced antigen uptake and presentation by macrophages and decreased
production of pro-inflammatory signals. N.meningitidis, in particular, has the ability to bind
human fH (hfH), an inhibitor of the complement alternative pathway (AP) [11, 13]. Three
meningococcal surface proteins, factor H binding protein (fHbp), Neisserial surface protein A
(NspA) and porin B2 (PorB2), have been implicated in hfH binding [10, 14]. Binding of a host
human protein such as fH, transferrin or CECAM1 to a vaccine antigen can interfere with
development of the immune response, as demonstrated by studies using human transgenic
mouse models [15–17]. There also are supporting data from a non-human primate model [18].
Based on these observations, a nOMV vaccine unable to bind hfH, and thus to inhibit the com-
plement alternative pathway, might elicit a stronger host immune response or have increased
adjuvant capacity compared to a wild-type counterpart.
To test this hypothesis, a nOMV vaccine derived fromMenB strain H44/76 lacking fHbp
and nspA genes was engineered, and immunogenicity was investigated in mice injected with
hfH [19]. This murine model is validated by the fact that treatment of mice suffering from age-
related macular degeneration with hfH reverses C3 renal deposition, thus confirming that hfH
has functional capacities in mice [19].
Material And Methods
Media and Reagents
Escherichia coli and N.meningitidis strains, plasmids and PCR primers used in this study are
listed in Table 1. DH5α Escherichia coli was grown in Luria-Bertani (LB) broth or on LB-agar
plates at 37°C. N.meningitidis was grown at 37°C in a humidified 5% CO2 atmosphere on GC
agar plates (Oxoid) supplemented with VitoX (2% v/v, Oxoid SR0090A) or, for genetic manip-
ulations, on Columbia Agar plates supplemented with horse blood (Oxoid) for serum bacteri-
cidal assay (SBA). Tryptone Soy Broth (Oxoid) was used for liquid cultures of N.meningitidis.
When required, media were supplemented with antibiotics (Sigma-Aldrich): ampicillin (amp)
100 μg/ml, kanamycin (kan) 50 μg/ml for E. coli and 100 μg/ml for N.meningitidis, erythromy-
cin (ery) 300 μg/ml for E. coli and 5 μg/ml for N.meningitidis, tetracycline (tet) 5 μg/ml for E.
coli and 2 μg/ml for N.meningitidis. Normal human serum (NHS) obtained from a healthy
adult human volunteer with no previous history of meningococcal disease or immunization
was used as complement source for SBA and hfH binding ELISA.
DNA cloning
Chemically competent E. coli DH5α were prepared using calcium chloride and transformation
for the propagation of plasmids was performed using standard methods[20]. Transformed cells
were plated onto selective LB agar and incubated at 37°C for 16–18 hours. N.meningitidis was
N.meningitidisModified nOMVs
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transformed using the spot transformation technique[21], using 10 μl (108 CFU) of bacterial
suspension from an overnight growth and 10 μl of PCR product plated over a 1–2 cm diameter
region on GC-VitoX agar. Reactions were incubated at 37°C, 5% CO2 for 4–8 hours before bac-
teria were plated onto selective GC-VitoX agar and incubated for 16–18 hours.
fHbp::ery, nspA::kan and lpxl1::tet mutations
The Δlpxl1::tetmutation was introduced in H44/76 as described previously [22] (strain H44/
76Lpxl1). In parallel, plasmids pMK-nspA and pMK-fHbp were designed with 700bp of both
upstream- and downstream- flanking regions of fHbp and nspA, respectively, with a unique
PacI restriction site interrupting or replacing the gene to be deleted. These constructs were
synthesised (GeneArt1, Life Technologies). The kanamycin cassette (aphA3) with its pro-
moter was amplified by PCR from pMK-Express[23] and the erythromycin cassette (ermC)
from pER2[24], using primers listed in Table 1. These antibiotics resistance cassettes were
inserted at the PacI restriction site into pMK-nspA or pMK-fHbp, respectively, leading to
pMK-nspAkan and pMK-fHbpEry. Integration of the cassettes into N.meningitidis was con-
firmed by restriction digestion and sequencing. PCRs to amplify the N.meningitidis DNA
region of pMK-nspAkan and pMK-fHbpEry were performed using primers pMK_forward and
pMK_reverse (Table 1). Purified DNA fragments (nspA::kan and fHbp::ery) were used to trans-
form sequentially H44/76Lpxl1 to generate a triple mutant H44/76 Δlpxl1::tet ΔnspA::kan
ΔfHbp::ery (further referred to as H44/76dis) as detailed in Fig 1. At each stage, mutations were
checked by PCRs, restriction profiling and confirmed by sequencing.
Extraction of native OMVs and characterization by SDS-PAGE, Western
blotting and ELISA
Native OMVs from H44/76Lpxl1 or H44/76dis strains (further referred to as nOMVLpxl1 and
nOMVdis, respectively) were extracted as previously described[25]: For each strain, bacteria
Table 1. Bacterial strains, plasmids and primers.
Bacterial strains: Origin:
E. coli DH5α Laboratory strains collection
N. meningitidis H44/76-SL Gift from R. Borrow
N. meningitidis H44/76 Δlpxl1::tet This work
N. meningitidis H44/76 ΔnspA ::kan ΔfHbp ::ery Δlpxl1::tet This work
Plasmids: Origin:
pMK-Express P. Langford (23)
pER2 Van der Voort et al., 1996 (24)
pMK-fHbp This work (GeneArt1)
pMK-nspA This work (GeneArt1)
pMK-fHbpEry This work
pMK-nspAKan This work
Primers: Sequence (5’-3’) Template
Kan_forward_PacI CCGTTAATTAAGGCCGAGCGCAGAAGTGGTC pMK-Express
Kan_reverse_PacI CCGTTAATTAATCGGCTCCGTCGATACTATG pMK-Express
Ery_forward_PacI GGCTTAATTAACGTTAAACCGTGTGCTCTAC pER2
Ery_reverse_PacI CCGTTAATTAACCCTCGAGGTCGACGGTATC pER2
pMK_forward TAGGGCGAATTGAAGGAAGG pMK-GeneArt
pMK_reverse TGGAAAGCGGGCAGTGAAAG pMK-GeneArt
doi:10.1371/journal.pone.0148840.t001
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from an overnight culture on GC agar plates supplemented with Vitox (Oxoid) were re-sus-
pended in 2,5ml Tryptone Soy Broth (Oxoid). 100μl of this suspension were plated on 20 fresh
GC-Vitox plates and incubated 12 hours at 37°C 5% CO2. The totality of the growth was re-
suspended in 40ml of OMV buffer (Tris-HCl 0.05M pH7.4, NaCl 0.15M, EDTA 0.01M) and
inactivated 40 minutes at 56°C before being sonicated 20x15sec on ice. Cell debris was removed
by centrifuging twice for 20 minutes at 16000xg. The supernatant collected was filtered using a
0.22μm filter, before being ultra-centrifuged for 1.5 hours at 250,000xg at 4°C. Finally, the pel-
let was washed three times with sterile water before being re-suspended in distilled water con-
taining 3% w/v sucrose and stored at 4°C. The expression of fHbp, NspA, PorA, PorB and
RmpM was characterized by Western blotting or ELISA as described below. nOMV prepara-
tions (6 μg of protein) were boiled for 5min in SDS-PAGE reducing buffer (Bio-Rad, Laemmli
1X #161–0737) before being separated by electrophoresis on a 8–16% Tris-Glycine gel (Biorad,
Criterion TGX) and stained with Coomassie blue (SimplyBlue, Invitrogen). For Western blot-
ting; the proteins were transferred to a nitrocellulose membrane (Whatman, Protran 0.2 μm)
using a Trans-Blot Turbo transfer system (Biorad). The membrane was blocked over-night
using TBST-BSA (TBS, 1%BSA, 0.1% Tween-20) and washed with TBST (TBS, 0.1% Tween-20).
The primary antibodies used were: anti-fHbp mAb JAR5 (provided by NIBSC through a gift
Fig 1. Construction of triple mutant strains. Step1: custom synthesis of plasmids pMK-nspA and pMK-
fHbp with a unique PacI restriction site replacing or interrupting nspA and fHbpORFs, respectively
(GeneArt1, Life technologies). Step 2: counter-clockwise insertion of an antibiotic resistance cassette at the
PacI restriction site leading to plasmids pMK-nspAkan and pMK-fHbpery. Step 3: generation of PCR
fragments using primers PMK_forward and pMK_reverse.
doi:10.1371/journal.pone.0148840.g001
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from Prof. Dan Granoff, Children's Hospital Oakland Research Institute, Oakland CA, USA)
diluted 1:5000, anti-PorA p1.7 (NIBSC) diluted 1:5000, anti-PorB p3.15 (NIBSC) diluted 1:750,
anti-NspAmAb 236-B2 and anti-RmpMmAb 173,G-1, diluted 1:2 (both gifts from Jan Kolberg,
Norwegian Institute of Public Health, Oslo). The secondary antibody was a goat anti-mouse IgG
HRP-conjugated pAb (Sigma-Aldrich) diluted 1:50000. Antibody binding was detected with ECL
Clarity Western Substrate (Biorad 170–5061) according to the manufacturer’s instructions using
a G:box Chemi imager (Syngene). The presence of the major antigen PorA at the surface of both
nOMVs was assessed by ELISA: Immulon1 2HBMicrotiterTM plates (Thermo-Scientific) were
coated with nOMVlpxl1 and nOMVdis at 20 μg/μl at 37°C for an hour. Following washes and a
blocking step with PBST-BSA 3% (PBST-BSA), anti-PorAmAb p1.7 (NIBSC) was added to all
wells. A goat anti-mouse IgG HRP-conjugate (Jackson Laboratories) was used as the secondary
antibody, and 3,30,5,50-Tetramethylbenzidine liquid substrate (TMB, Sigma-Aldrich) used for
detection according to the manufacturer’s instructions.
Evaluation of the binding of human fH to nOMVs
96-wells plates were coated with different concentrations of nOMVs (5 μg/ml, 10 μg/ml or
20 μg/ml) overnight at 4°C in the absence of detergent. After washing with PBST (PBS1X,
Tween1 20 0.05%), plates were blocked in PBST-BSA 3%. Normal human serum (NHS) was
heated at 56°C for 30 min to inactivate the complement, thus preventing C3b deposition,
which could serve as an alternative ligand for hfH, on bacteria. This treatment is known not to
affect hfH binding properties to fHbp [26]. The wells were washed and incubated with different
concentrations of de-complemented NHS (100%, 50%, 25% or none) or with purified hfH
(Complement Technologies) for 10 mins at 37°C. Primary and secondary antibodies were
diluted in TBST-BSA3% and incubations were performed at room temperature for 1 hour. The
antibodies used were: mouse anti-hfH mAb (AbD Serotec MCA508G) diluted 1:250 and goat
anti-mouse IgG (Jackson Laboratories) diluted 1:25000. Antibody binding was determined as
described above.
Mouse immunizations
All procedures were performed in accordance with the terms of the UK Home Office Animals
Act Project License. Procedures were approved by the University of Oxford Animal Care and
Ethical Review Committee. Samples were obtained following terminal general anaesthesia. In
all experiments, groups of five to eight 6-week old female C57bl/6 mice (Harlan) were immu-
nized intramuscularly with nOMVLpxl1 or nOMVdis, at day 0 and 28. Vaccines contained
5.1 mg/ml Al(OH)3 as an adjuvant, according to the manufacturer’s instructions (Brenntag
Biosector, Denmark). Mice were immunized at day 0 and 28 with alum-adsorbed vaccines at
two different concentrations (2.5 or 5 μg of proteins). Blood was collected under terminal gen-
eral anaesthesia two weeks after the second dose (day 42). To investigate the effect of the
absence of hfH binding to nOMVdis, nOMVs (5 μg) were pre-incubated for 1 hour with
800 μg/ml hfH or 800 μg/ml hSA (Human Serum Albumin, Sigma-Aldrich) as an irrelevant
control protein, in phosphate buffered saline pH 7.2. To mimic the presence of hfH in vivo in
mice[19], groups of C57bl/6 mice were injected intraperitoneally with 500 μg hfH or 500 μg
hSA 24 hours and 30 mins prior to immunization with 5 μg non-adjuvanted nOMVdis or
nOMVlpxl1 at day 0. Two control groups consisted of non-immunized mice injected with or
without 500μg hfH. Levels of hfH in mice serum were assessed by ELISA on 50μl of blood col-
lected by tail bleed at various time points (30 mins, 24 hours, 48 hours and 72 hours) after the
second hfH injection. Blood was collected 2 weeks post immunization. Sera were separated by
centrifugation and stored frozen at -20°Cuntil further analysis.
N.meningitidisModified nOMVs
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Evaluation of hfH levels and antibody responses in murine serum
hfH levels in mice were evaluated by sandwich ELISA. Briefly, Immulon1 2HB plates were
coated for one hour at 37°C with sheep anti-hfH antibody (AbD Serotec #4400–9504). Mouse
sera were added to the plates and incubated for an hour at room temperature under gentle
rocking. Purified hfH was used as a standard (1 mg/ml, Complement Technology Inc, #A137).
Mouse anti-hfH mAb (AdB Serotec MCA508G) was added to the plates prior to the secondary
goat anti-mouse IgG HRP-conjugated antibody (Jackson Laboratories), and the reaction was
revealed as described above. For antigen-specific antibody responses, whole cell, recombinant
PorA and fHbp ELISA were performed as described previously [22]. IgG titres were calculated
as the reciprocal of the last dilution giving an optical density readout superior to the cut-off
(four time the average O.D. obtained with naïve sera).
Serum Bactericidal Assay (SBA)
Human complement-mediated SBA titres were measured in pooled or individual sera when
these were available in sufficient quantities, using wild-type 44/76-SL as the target strain (gift
from Prof R. Borrow, PHE North West Laboratory, Manchester). The complement source was
obtained from healthy donors who had provided written informed consent (Ethics number 10/
H0102/23). The donation trial was conducted in accordance with the clinical trial protocol and
the principles of the Declaration of Helsinki (2008) and the International Conference on
Harmonization (ICH) Good Clinical Practices standards. The analyses were performed in
microtiter plates by the standardized method [27]. CFU were counted using an automated
counter (Sorcerer; Perceptive Instruments, Haverhill, Suffolk, United Kingdom). The bacteri-
cidal titers were defined as the reciprocal of the serum dilution that killed at least 50% of the
organisms.
Statistical analysis
Calculations were carried out using GraphPad PRISM version 6.00 for Mac (GraphPad Soft-
ware, San Diego California, USA, www.graphpad.com). A one-way analysis of variance
(ANOVA) was conducted on the log10 transformed antibody titers data to test for differences
between groups. If the data appeared to be non-normal, non-parametric Kruskal Wallis analy-
sis was carried out with Dunn’s adjusted p-values for multiple comparisons.
Results
Characterization of nOMVs
The strains H44/76 Δlpxl1::tet and H44/76 Δlpxl1::tet ΔnspA::kan ΔfHbp::ery were confirmed
by PCR and restriction digestion profiling. nOMVlpxl1 and nOMVdis were produced from H44/
76 Δlpxl1::tet and H44/76 Δlpxl1::tet ΔnspA::kan ΔfHbp::ery, respectively. Evaluation of protein
concentrations showed similar yields between preparations (7.25 μg/μl for nOMVlpxl1 against
4.85 μg/μl for nOMVdis). As expected, ΔfHbp::ery and ΔnspA::kanmutations led to a total sup-
pression of fHbp and NspA protein expression in nOMVdis compared to nOMVlpxl1 (Fig 2A).
These mutations did not impact on PorA expression, a major surface antigen of N. meningitidis
[28], as shown by ELISA (Fig 2B), nor that of other antigens such as PorB and RmpM (data not
shown).
Absence of fHbp and NspA reduces hfH binding to nOMVs
While nOMVLpxl1 bound at similar levels to the three concentrations of purified hfH tested
(with ODs of 1.15, 1.39 and 1.27 for the 200, 400 and 800 μg/ml hfH concentrations,
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respectively), binding of purified hfH to nOMVdis was reduced, with the OD being on average
35.6% less as compared with that of nOMVlpxl1 (OD 0.30 to 0.58, Fig 3A). When NHS was
used as a source of hfH, a dose–response was observed with nOMVlpxl1, with ODs ranging
from 0.30 to 1.27. By contrast, the ODs observed with nOMVdis ranged from 0.18 to 0.25 (Fig
3B). Thus, absence of fHbp and NspA substantially reduced hfH binding to nOMVdis.
Absence of fHbp and NspA did not impair nOMVs immunogenicity in
mice
fHbp is a major surface-exposed antigen of N.meningitidis, being highly expressed on strain
H44/76 [29, 30], and it is one of the most promising vaccine candidates against capsular group
Fig 2. Characterization of nOMVs. A. Expression of fHbp and NspA in the nOMVs. nOMVlpxl1 (lanes 1 and
3) and nOMVdis (lanes 2 and 4) proteins were separated by SDS-PAGE followed by separate western blotting
against fHbp (lane 1 and 2), or NspA (lane 3 and 4). Molecular weight of protein standard (MW) is indicated.
B. Expression of PorA in the nOMVs. The relative amount of PorA in nOMVdis (dash-line) was compared to
nOMVlpxl1 (plain line) by ELISA with α-PorA mAb (p1.7). Data presented are the means ± S.D. of two
independent assays, each performed in duplicate.
doi:10.1371/journal.pone.0148840.g002
Fig 3. hfH binding to nOMVdis as compared to nOMVlpxl1. A. Binding of purified hfH at different
concentrations (200, 400 and 800 μg/ml) or of de-complemented NHS to 20 μg/ml of nOMVlpxl1 (hashed bars)
and nOMVdis (dark bars). Means ± S.D. of two independent assays, each performed in duplicate, are
presented.B. Detection of hfH binding from NHS on nOMVs at three different concentrations of nOMVs (5, 10
or 20 μg/ml) and three different concentrations of de-complemented NHS (25, 50 or 100%).
doi:10.1371/journal.pone.0148840.g003
N.meningitidisModified nOMVs
PLOSONE | DOI:10.1371/journal.pone.0148840 February 12, 2016 7 / 15
B N. meningitidis [31]. Therefore, the deletion of this antigen could lead to a loss in immunoge-
nicity of nOMVdis compared to nOMVlpxl1 in wild-type mice. As shown in Fig 4A, however,
C57BL/6 mice immunized with nOMVdis produced similar amounts of H44/76 whole cell- spe-
cific IgG as compared to mice immunized with nOMVlpxl1 after the first and second injections.
The pooled bactericidal antibody titers were also similar, with titers of 1:256 and 1:512 induced
by 2.5 and 5 μg nOMVlpxl1, respectively and 1:512 with nOMVdis (Fig 4B). Individual SBA
analysis at day 42 suggested that the SBA in pooled sera is an over-estimation of the average
response in individual mice, but confirmed that no difference between groups was detectable
(Fig 4C). Thus absence of NspA and fHbp did not impair nor increase the immunogenicity of
nOMVdis suggesting that these 2 proteins have a limited contribution to the nOMV-induced
antibody response in this model.
Antibody responses in mice in the presence of hfH
Mice were injected intraperitoneally with hfH prior to vaccination to reach the standard
human serum concentration (500 μg– 800 μg/ml). While hfH was not detectable in mice prior
to hfH injection, the concentration of hfH in mouse serum reached around 750 μg/ml after two
IP injections of 500 μg hfH 24 hours apart (Fig 5A). This concentration is close to the maxi-
mum of the human range of hfH concentration (500–800 μg/ml). However, the bactericidal
titer elicited by one vaccination with nOMVdis in mice pre-injected with hfH (1:64) was not
significantly different from that obtained with nOMVlpxl1 (1:128, Fig 5B). It was also similar
for both nOMV preparations in control mice pre-injected with human serum albumin (1:128,
Fig 5B), demonstrating that in this model, deletion of fHbp and nspA had no impact on the
nOMV immunogenicity. Individual SBA titers were lower than the SBA titer obtained with the
pooled serum, but confirmed that no difference was observed between the groups (Fig 5C). To
confirm that the administered hfH induced the expected decreased antibody response against
fHbp, individual fHbp-specific antibody responses of mice injected with human fH or the con-
trol human serum albumin (hSA) and immunized with H44/76Lpxl1 OMV (containing fHbp)
were measured in sera that were available. Although not all sera were available, the ELISA titers
induced against rfHbp after a single dose H44/76Lpxl1 OMV were lower in the group that
received hfH passive administration as compared to the control (Fig 5D, p = 0.016, unpaired t
test). Of note, no booster dose was administered to avoid the confounding effect of raising
anti-hfH antibodies in mice. Bactericidal assays were performed against a PorA off strain to
investigate whether the antibody response against other minor (non-PorA) antigens are
affected by deleting fHbp and nspA. However SBA titers induced by one injection of nOMV
against a PorA off strain were very low or undetectable, and no statistically significant differ-
ence were detected between groups (data not shown).
Antibody response in mice following immunization with nOMVlpxl1 or
nOMVdis pre-incubated with purified hfH
In the previous experiment, intraperitoneal injections led to short-lived levels of hfH in mice,
and raised the possibility that there was not enough hfH in the appropriate compartment at the
time of priming the immune response. Therefore, a model of ex vivo pre-incubation of the vac-
cines (nOMVlpxl1 or nOMVdis) with hfH at 800 μg/ml was established. In this experiment, the
vaccines were not adjuvanted with aluminum hydroxide to avoid any putative inhibition of the
binding between nOMVs and hfH by alum. To avoid the confounding factor of raising anti-
hfH in mice, only a single injection was performed. The nOMV-specific IgG response in mice
immunized with nOMVdis pre-incubated with hfH was similar to the controls i.e. nOMVdis
incubated with an irrelevant (hSA) or without hfH pre-incubation at day 14 (Fig 6A). The
N.meningitidisModified nOMVs
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Fig 4. nOMVs immunogenicity in C57Bl/6 mice. A.Whole cell-specific IgG titres in C57/bl6 mice sera
following immunization with 5 μg nOMVlpxl1 or nOMVdis. Data represent the individual antibody titers in each
animal, and the geometric mean of the group, at day 14 (2 weeks post first injection) and day 42 (2 weeks
post second injection). These results are representative of 2 independent mouse experiments. There was no
statistical difference between the two groups at day 14 (p = 0.085) nor at day 42 (p = 0.069) by two-tailed
Mann-Whitney test.B. SBA titers against 44/76-SL wild-type in C57bl/6 mice pooled sera at day 42 (14 days
following booster immunization) with 2,5μg or 5μg of nOMVlpxl1 or nOMVdis. C. Individual SBA titers against
N.meningitidisModified nOMVs
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same level of IgG production was observed in mice immunized with nOMVlpxl1 alone or pre-
incubated with hfH or hSA, suggesting that the reduced binding of hfH to the nOMVdis did
not have any quantitative effect on the antibody response. Similarly, the SBA against 44/76-SL
(Fig 6B) did not show any significant difference (more than a titer) between the six vaccinated
groups (titers of 1:64–1:128), suggesting that reduced binding of hfH to nOMVdis did not
enhance the immune response. At day 28, a booster dose was administered after pre-incuba-
tion as described above, and individual SBA titers analyzed two weeks later (Fig 6C). Results
confirmed that no difference was observed between groups. SBA titers against a PorA off strain
were also measured to investigate whether the antibody response against other minor (non-
PorA) antigens was modified, but SBA titers against a PorA off strain were very low or unde-
tectable, and there were no statistically significant differences between groups (data not
shown).
Discussion
The insertion of mutations in N.meningitidisH44/76 led to a total suppression of fHbp and
NspA expression in nOMVdis, while the amount of PorA remained unaffected. In the triple
44/76-SL at day 42, dots represent individual animals, the geometric mean and 95% confidence interval are
represented as horizontal bars.
doi:10.1371/journal.pone.0148840.g004
Fig 5. Effect of the presence of hfH in mice on the nOMV immunogenicity. A. Evolution of hfH
concentration in mouse serum over time after two IP injection of 0.5mg purified hfH (black arrows) 24 and 0.5
hours prior to immunization (grey arrow). B. Serum Bactericidal Assay (SBA) titers against 44/76-SL wild-
type in pooled sera from C57bl/6 mice pre-injected with 800 μg/ml hfH or hSA, 14 days following
immunization with 5 μg of nOMVlpxl1 or nOMVdis. C. Individual SBA titers against 44/76-SL, dots represent
individual animalsD. Individual ELISA titers against rfHbp induced after one dose of H44/76Lpxl1 OMV in mice
pre-injected with hfH or hSA, *p = 0.016, not all sera were available.C, D dots represent individual animals,
the geometric mean and 95% confidence interval are represented as horizontal bars.
doi:10.1371/journal.pone.0148840.g005
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Fig 6. Immunogenicity of nOMVs pre-incubated with purified hfH. Specific IgG response in C57/bl6 mice
sera following immunization with 5 μg nOMVlpxl1 and nOMVdis pre-incubated or not with 800 μg/ml hfH or
hSA, assessed by ELISA using heat-inactivated H44/76 whole cells. Data represent the individual antibody
titers in each animal, and the geometric mean of the group, at days 14 (A) (2 weeks post single injection)
There were no statistical differences between the 6 groups according to statistical analysis performed on log-
transformed data using Kruskal-Wallis test with Dunn’s multiple comparison correction. B. SBA titers against
44/76-SL in C57bl/6 mice pooled sera at day 14. C. Individual SBA titers at day 42 (2 weeks post second
N.meningitidisModified nOMVs
PLOSONE | DOI:10.1371/journal.pone.0148840 February 12, 2016 11 / 15
mutant H44/76dis there was a reduction in hfH binding of around 35%, consistent with previ-
ous observations with ΔfHbpΔnspAH44/76 mutants [32]. However, despite the reduction of
human fH binding in H44/76dis, immunogenicity of derived nOMVdis in mice was not signifi-
cantly different from nOMVlpxl1 in the presence of hfH, either injected into mice or directly
pre-incubated with the nOMVs prior to injection.
In this study, hfH binding to nOMVdis was reduced but not abrogated. Lewis and collabora-
tors obtained similar results with a capsular group B N.meningitidis strain in which fHbp and
nspA were deleted and the LPS unsialylated [32], and showed that PorB2 is implicated in the
inhibition of the complement alternative pathway by interacting with hfH [33]. However H44/
76 does not express PorB2. So far, other meningococcal components have been implicated in
hfH sequestration such as PorB3 in certain strains [34]. Our work suggests the existence of one
(or several) other meningococcal proteins able to inhibit complement alternative pathway by
sequestering hfH and highlights the multiplicity and complexity of the strategies capsular
group B N.meningitidis has evolved to evade the human complement cascade. The hfH bind-
ing may not have been sufficiently suppressed by deleting fHbp and nspA, and the residual
binding thus makes it difficult to interpret the importance of partially reduced hfH binding on
overall immunogenicity. Of note, N.meningitidis is capable of binding the serum complement
inhibitor C4bp [9] and activated vitronectin, which could also impact on immunogenicity.
We had hypothesized that nOMVdis would induce higher complement activation compared
to hfH binding nOMVs, which in turn would result in an increased adaptive response to the
nOMVs [12], as previously observed with fHbp antigen [35]. In a previous study, increased
antibody response was observed against an OMV containing a point-mutated fHbp unable to
bind hfH, as compared to an OMV containing a wild type fHbp able to bind hfH [36]. There-
fore, the increased immunogenicity was observed against the hfH ligand (fHbp), in contrast to
our study where fHbp and NspA are absent and the remaining hfH ligand on the disarmed
OMV is unknown. Direct binding of the complement inhibitor to the antigen may be necessary
for complement inactivation to impact on the antigen’s resulting immunogenicity. An example
of this phenomenon was shown in human CEACAM transgenic mice, only the responses to
the ligand for human CEACAM, Opa, was decreased, but not the responses to the OMV as
whole [17].
The relevance of the murine model could be questioned since complement evasion by N.
meningitidis by complement inhibitor sequestration is specific to humans. A hypothesis could
be that mice lack other factors implicated in N.meningitidis resistance to complement. How-
ever, treatment of mice suffering from age-related macular degeneration with hfH reverses C3
renal deposition[19], thus suggesting that hfH has functional capacities in mice. In addition,
our data suggest, despite the low number of mice, that the passive administration of hfH
decreased the antibody response to fHbp in mice immunized with H44/76Lpxl1 OMV, in agree-
ment with previous published results [15, 36]. Transgenic mice expressing full length human
fH [15], or a chimeric fH consisting of mouse fH CCPs 1–5 and 9–20 (enabling interaction
with murine C3b and other complement components), flanking hfH CCPs 6–8 (allowing bind-
ing to fHbp) as previously described [37] may have been better predictor of the effect in
human, but these models were not available for testing. Our results suggest that the effect of
human fH on the immunogenicity of fHbp occurs at a step soon following immunization.
When human fH is injected, the human fH is present only for a few days at best (serum hfH
concentration peaks 24hours after injection, and is down to very low levels at 96 hours[19]),
immunization), dots represent individual animals, the geometric mean and 95% confidence interval are
represented as horizontal bars.
doi:10.1371/journal.pone.0148840.g006
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unlike the human fH transgenic mice, yet its effect on fHbp immunogenicity is noted. This pro-
vides a mechanistic insight: it is likely that antigen presentation and processing is affected by
fH binding to fHbp, as opposed to further downstream processes.
We observed that nOMVs lacking fHbp are as immunogenic as wild-type nOMVs. In the
absence of fHbp and NspA, both nOMV-specific IgG responses and SBA titers in mice are sim-
ilar to nOMVs extracted from the wild-type strain, which is in agreement with previous obser-
vations that SBA responses induced by OMVs are largely directed against PorA[38]. Depletion
of antigens such as fHbp could unmask sub-dominant epitopes, and support a re-direction of
the immune response towards other antigens. Creating a triple ΔfHbp, ΔnspA, ΔporAmutant
would allow the assessment of whether the absence of these major antigens reveals sub-domi-
nant antigens or cryptic epitopes. Moreover, PorA also binds the complement inhibitor C4bp,
allowing N.meningitidis to escape the classical- and lectin complement pathways [9]. Disrupt-
ing hfH binding as well as C4bp binding to N.meningitidismight ameliorate the adjuvant
properties of nOMVs extracted from such a strain, as OMVs have been considered for their
carrier and adjuvant properties[5], in particular, for Haemophilus influenzae type b and malaria
vaccines candidates [39, 40].
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